Case Study
The Psychiatry Consortium – exploring new treatments for mental health conditions
Medicines discovery for challenging diseases requires a collaborative approach with a patient focus. In 2019 the Medicines Discovery Catapult established the Psychiatry Consortium as one of its patient focussed partnerships. It is a strategic collaboration of two leading medical research charities and seven international pharmaceutical companies, focusing on the unmet therapeutic needs of people living with mental health conditions.